ANALYSIS OF HYPERTHYROIDISM REMISSION AFTER SUSPENSION OF THIONAMIDE WITH PROLONGED USE: A CROSS-CROSS-SET STUDY

• DOI: 10.22533/at.ed.1593992304122

• Palavras-chave: Hyperthyroidism; Thionamides; Graves' disease.

• Keywords: Hyperthyroidism; Thionamides; Graves' disease.

• Abstract:

  Goals: evaluate the laboratory evolution of hyperthyroid patients, who used thionamides for at least 3 years, after discontinuing the drug. Methods: Cross-sectional study with an analytical component, developed between 2017-2018 in Limoeiro-PE- Brazil, using data from medical records in UPAE patients, on hormonal dosage values for one year after stopping the medication. Results: Among the 56 patients, women were 82.1%, age <40 years in 51.8%, methimazole as the drug used in 91.1%. Most patients had initial TRAb ≥ 3.5 IU/L (80.4%), TRAb in suspension <3.0 IU/L (80.4%) and TSH in suspension 3.0 IU/L in 58.9%. After discontinuation of the drug, 53.6% of patients remitted. Remission was present in 100% of those with initial TRAb <3.5IU/L and in 42.2% of those with initial TRAb ≥ 3.5IU/L. None of the patients with TRAb on drug suspension ≥ 3.0IU/L remitted. Of those who had TSH < 3.0 IU/L upon suspension, 13% remitted, while those with TSH 3.0 IU/L 81.8% achieved remission. Conclusion: remission of hyperthyroidism occurs in about half of patients who use antithyroid drugs for at least three years. The value of initial TRAb and TRAb and TSH after stopping the drug are also predictors of disease remission.